Physician profile
Inna Shifrin
NPI 1710967971
$21,406.81
in general payments reported to CMS, 2019-2025
68 companies · $3,773 in 2025
The $3,773 reported for 2025 was more than what 97% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,685 · 2020: $2,178 · 2021: $3,022 · 2022: $2,588 · 2023: $3,232 · 2024: $3,930 · 2025: $3,773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,927.61 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,773.13 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $2,247.53 | 2019-2025 | Breztri, Farxiga, Tezspire |
| Glaxosmithkline, LLC. | $1,752.36 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,616.81 | 2019-2025 | Trulance, Xifaxan |
| Lilly USA, LLC | $1,183.64 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $855.63 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Sanofi-Aventis U.S. LLC | $821.78 | 2019-2024 | |
| Philips North America LLC | $791.53 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und, (8874) Incourage |
| Novartis Pharmaceuticals Corporation | $762.00 | 2019-2024 | |
| Novo Nordisk INC | $714.63 | 2019-2025 | Ozempic, Rybelsus |
| Genzyme Corporation | $669.53 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $663.08 | 2019-2025 | Verquvo, Capvaxive, Lagevrio |
| Aimmune Therapeutics, INC. | $473.49 | 2024-2025 | Zenpep |
| Genentech USA, INC. | $344.59 | 2019-2022 | |
| Abbott Laboratories | $323.39 | 2021-2025 | Freestyle Libre 3 |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $318.81 | 2021-2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $309.00 | 2020-2024 | Xarelto |
| Shield Therapeutics INC | $306.19 | 2023-2025 | Accrufer |
| Alnylam Pharmaceuticals INC. | $295.47 | 2023-2025 | Amvuttra |
| Allergan, INC. | $256.62 | 2019-2020 | |
| Pfizer INC. | $247.01 | 2019-2025 | |
| Axsome Therapeutics, INC. | $242.79 | 2024-2025 | Auvelity |
| Avanir Pharmaceuticals, INC. | $229.00 | 2019-2022 | |
| Amarin Pharma, INC. | $169.93 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $147.34 | 2023-2025 | Gemtesa |
| Exact Sciences Corporation | $130.54 | 2023-2024 | Cologuard Collection Kit |
| Ardelyx, INC. | $129.07 | 2023-2024 | Ibsrela |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $126.99 | 2024-2025 | Caplyta |
| Regeneron Healthcare Solutions, INC. | $124.73 | 2021-2024 | Dupixent |
| Ibsa Pharma INC. | $118.82 | 2019-2020 | |
| Astellas Pharma US INC | $114.36 | 2019-2020 | |
| Amgen INC. | $113.16 | 2019-2023 | Repatha, Otezla |
| Teva Pharmaceuticals USA, INC. | $111.54 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $106.95 | 2022-2023 | Livalo, Seglentis |
| Sunovion Pharmaceuticals INC. | $106.28 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $105.10 | 2019-2024 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $104.02 | 2021-2024 | Trintellix |
| Comsort, INC | $100.00 | 2019 | |
| Esperion Therapeutics, INC. | $98.64 | 2021-2024 | Nexletol |
| Lundbeck LLC | $98.35 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $92.41 | 2024 | Voquezna |
| Bausch Health US, LLC | $87.38 | 2024-2025 | Aplenzin |
| Verona Pharma, INC. | $81.52 | 2025 | Ohtuvayre |
| Otsuka America Pharmaceutical, INC. | $72.82 | 2023-2024 | Nuedexta, Rexulti |
| Paratek Pharmaceuticals, INC. | $72.72 | 2023-2024 | Nuzyra |
| Nestle Healthcare Nutrition INC. | $70.90 | 2020-2023 | |
| Corium, LLC | $68.14 | 2023 | Azstarys |
| Scynexis, INC. | $51.54 | 2022 | |
| Corcept Therapeutics | $51.00 | 2024 | Korlym |
| Vivus LLC | $47.60 | 2019 | |
| Nabriva Therapeutics, Plc | $46.75 | 2021-2022 | |
| Electromed, INC. | $45.78 | 2022-2025 | Smartvest |
| Almatica Pharma LLC | $44.46 | 2021 | |
| Intra-Sana Laboratories | $41.34 | 2023-2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Baxter Healthcare | $39.48 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Alfasigma USA, INC. | $37.01 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $30.39 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $27.71 | 2021 | |
| Currax Pharmaceuticals LLC | $25.92 | 2021 | |
| Insmed, INC. | $23.87 | 2025 | Brinsupri |
| Eisai INC. | $23.44 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $21.64 | 2024 | Kristalose |
| Idorsia Pharmaceuticals US INC | $20.87 | 2025 | Quviviq |
| Agios Pharmaceuticals, INC. | $19.31 | 2024 | Pyrukynd |
| Melinta Therapeutics, LLC | $16.86 | 2019 | |
| Hikma Pharmaceuticals USA | $15.30 | 2019 | |
| Clarus Therapeutics INC. | $14.24 | 2021 | |
| Mycovia Pharmaceuticals, INC. | $12.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inna Shifrin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.